Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.

Journal of biomolecular structure & dynamics - 1 Jun 2026

Mallen Justice Josiah, Sharma Shilpa, Hasan Md Nazmul, Saha Arjun

Abstract excerpt

Kinases are pivotal in regulating signaling pathways, and their dysregulation is associated with various diseases, including cancers, making them prime therapeutic targets. Bruton's Tyrosine Kinase (BTK) is crucial for B-cell development, and BTK inhibitors have proven effective in treating B-cell malignancies like Chronic Lymphocytic Leukemia (CLL). Non-covalent inhibitors offer a promising therapeutic approach...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Binding Sites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catalytic Domain

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Ligands

Share to Molecular Dynamics Simulation

Share to Protein Binding

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 40372209
DOI: 10.1080/07391102.2025.2502140

Genes

BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.PMID 40372209Read ↗

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.Semantic proximity Read ↗

Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK.Semantic proximity Read ↗

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.Semantic proximity Read ↗

Virtual Screening and Identification of Non-covalent Reversible Small-molecule BTK Inhibitors from a Library of Known Bioactive CompoundsSemantic proximity Read ↗

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.Semantic proximity Read ↗

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and functionSemantic proximity Read ↗

Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.Semantic proximity Read ↗

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.Semantic proximity Read ↗

Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase.Semantic proximity Read ↗

Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.Semantic proximity Read ↗

Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasmsSemantic proximity Read ↗

Rare deleterious mutations in Bruton's tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.